Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared on X:
“LITESPARK-011 | RCC avanzado.
Belzutifan + lenvatinib vs cabozantinib after progression to anti-PD-1/PD-L1:
- SLP: 14.8 vs 10.7 meses
- HR 0.70 (IC 95% 0.59-0.84; p<0.0001)
- SG: 34.9 vs 27.6 meses
- HR 0.85 (IC 95% 0.68-1.05; p=0.061)
The SLP improved significantly, while the difference in SG did not reach statistical significance.
Toxicity grade ≥3: 84% vs 83%.
A relevant result for post-immunotherapy treatment in clear cell CCR.”
Title: Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
Authors: Robert J Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto, Roberto Iacovelli, Elena Verzoni, Cristina Suárez, Masatoshi Eto, Hernan J Cutuli, Camillo Porta, Ray Manneh Kopp, Sylvie Rottey, Guillermo de Velasco, Begoña P Valderrama, Arun A Azad, Ugo De Giorgi, Michel Pavic, Piotr Tomczak, Robert Figlin, Hans M Westgeest, Annalisa Guida, Andrea Necchi, Fabio A Schutz, Britt B M Suelmann, John B A G Haanen, Sammy Shuai Yuan, Rodolfo F Perini, Ding Wang, Daniel Y C Heng, Manuela Schmidinger
You may be interested:
FDA Approved Belzutifan Plus Lenvatinib in Advanced ccRCC
